image
Healthcare - Medical - Diagnostics & Research - NASDAQ - DE
$ 1.98
-2.94 %
$ 7.55 M
Market Cap
-0.09
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 23, 2025.

The intrinsic value of one MYNZ stock under the worst case scenario is HIDDEN Compared to the current market price of 1.98 USD, Mainz Biomed B.V. is HIDDEN

This DCF valuation model was last updated on May, 23, 2025.

The intrinsic value of one MYNZ stock under the base case scenario is HIDDEN Compared to the current market price of 1.98 USD, Mainz Biomed B.V. is HIDDEN

This DCF valuation model was last updated on May, 23, 2025.

The intrinsic value of one MYNZ stock under the best case scenario is HIDDEN Compared to the current market price of 1.98 USD, Mainz Biomed B.V. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart MYNZ

image
$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.0$3.0$3.0$2.0$2.0$1.0$1.0Dec '24Dec '2420252025Feb '25Feb '25Mar '25Mar '25Apr '25Apr '25May '25May '25Jun '25Jun '25
FINANCIALS
894 K REVENUE
-0.17%
-18.7 M OPERATING INCOME
29.83%
-21.7 M NET INCOME
17.66%
-17.1 M OPERATING CASH FLOW
22.10%
-199 K INVESTING CASH FLOW
89.53%
16.6 M FINANCING CASH FLOW
16.68%
521 K REVENUE
142.49%
-9.81 M OPERATING INCOME
-48.81%
-11 M NET INCOME
-112.68%
-8.14 M OPERATING CASH FLOW
-74.96%
-421 K INVESTING CASH FLOW
-12.39%
2.55 M FINANCING CASH FLOW
-26.39%
Balance Sheet Mainz Biomed B.V.
image
Current Assets 7.84 M
Cash & Short-Term Investments 6.24 M
Receivables 214 K
Other Current Assets 1.39 M
Non-Current Assets 5.39 M
Long-Term Investments 0
PP&E 2.38 M
Other Non-Current Assets 3.02 M
47.10 %10.53 %17.95 %22.79 %Total Assets$13.2m
Current Liabilities 5.95 M
Accounts Payable 1.25 M
Short-Term Debt 2.41 M
Other Current Liabilities 2.29 M
Non-Current Liabilities 1.24 M
Long-Term Debt 866 K
Other Non-Current Liabilities 376 K
17.44 %33.45 %31.84 %12.04 %5.23 %Total Liabilities$7.2m
EFFICIENCY
Earnings Waterfall Mainz Biomed B.V.
image
Revenue 894 K
Cost Of Revenue 319 K
Gross Profit 575 K
Operating Expenses 19.3 M
Operating Income -18.7 M
Other Expenses 2.96 M
Net Income -21.7 M
5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)894k(319k)575k(19m)(19m)(3m)(22m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
64.31% GROSS MARGIN
64.31%
-2091.23% OPERATING MARGIN
-2091.23%
-2421.80% NET MARGIN
-2421.80%
-358.07% ROE
-358.07%
-163.55% ROA
-163.55%
-192.86% ROIC
-192.86%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Mainz Biomed B.V.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)202020202021202120222022202320232024202420252025
Net Income -21.7 M
Depreciation & Amortization 1.02 M
Capital Expenditures -255 K
Stock-Based Compensation 1.14 M
Change in Working Capital 51.7 K
Others 2.31 M
Free Cash Flow -17.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Mainz Biomed B.V.
image
MYNZ has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Mainz Biomed B.V.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants BERKELEY, Calif. and MAINZ, Germany, May 19, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 1 month ago
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, Calif. and MAINZ, Germany, May 16, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 1 month ago
Mainz Biomed Enters into Technology Partnership with EDX Medical Group BERKELEY, Calif. and MAINZ, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 1 month ago
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval BERKELEY, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 1 month ago
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study 2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed's Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples Study is on Track to Report Top-Line Results in Fourth Quarter 2025 BERKELEY, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 2 months ago
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood Samples Mainz Biomed Enters into Exclusive Licensing Agreement for the Portfolio of mRNA Biomarkers, with Continued Development of Machine Learning AI-Based Algorithm Based on Liquid Biosciences EMERGE Platform BERKELEY, Calif. and MAINZ, Germany, March 13, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 3 months ago
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention BERKELEY, Calif. and MAINZ, Germany, March 03, 2025 (GLOBE NEWSWIRE) --  Mainz Biomed N.V. globenewswire.com - 3 months ago
Mainz Biomed Expands into Switzerland with labor team w BERKELEY, Calif. and MAINZ, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 3 months ago
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month BERKELEY, Calif. and MAINZ, Germany, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 4 months ago
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements BERKELEY, Calif. and MAINZ, Germany, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that on January 23, 2025, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that it has regained compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market set forth in Listing Rule 5550(b)(1). globenewswire.com - 4 months ago
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population eAArly DETECT 2 feasibility study designed to validate earlier results on advanced adenomas over a large population of average risk patients Multi-center study expected to complete enrollment in the second half and reporting in the Fourth Quarter of 2025 BERKELEY, Calif. and MAINZ, Germany, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the launch of eAArly DETECT 2, a U.S. feasibility study to evaluate the Company's next generation colorectal cancer (CRC) test, integrating its proprietary mRNA biomarkers, AI developed algorithm and FIT test, over a population of approximately 2,000 patients, all of average risk, to validate the industry leading results of previous feasibility studies, which included average risk and identified risk patients. globenewswire.com - 4 months ago
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 6 months ago
8. Profile Summary

Mainz Biomed B.V. MYNZ

image
COUNTRY DE
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 7.55 M
Dividend Yield 0.00%
Description Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Contact Robert Koch Strasse 50, Mainz, 55129 https://mainzbiomed.com
IPO Date Nov. 5, 2021
Employees 19
Officers Mr. Stefan Erlach Head of Human Resources Dr. Frank Krieg-Schneider Chief Technology Officer Dr. Christopher Von Toerne P.M.P., Ph.D. Chief Operating Officer Dr. Moritz Eidens Ph.D. Chief Science Officer & Executive Director Mr. Philipp Freese Chief Business Officer Mr. Guido Baechler Chief Executive Officer & Executive Director